TG Therapeutics | TGTX - Operating Profit


TG Therapeutics reported $21.67M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Alaunos Therapeutics USD -1.01M 175K Mar/2026
Amgen USD 4.61B 777M Jun/2026
Ardelyx USD -32.79M 37.89M Mar/2026
Arrowhead Research USD -141.26M 182.07M Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
Biogen USD -243.8M 758.1M Jun/2026
Corcept Therapeutics USD 41.3M 90.9M Jun/2026
Curis USD -11.52M 3.64M Mar/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
J&J USD 7.48B 860M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Novartis USD 4.75B 515M Jun/2026
Novavax USD 20.94M 100.32M Dec/2025
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026
Verastem USD -44.9M 3.42M Mar/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026